Exclusive interview with Thomas Zeller

 Thomas Zeller (Germany) answers the following questions :

- Why come to RHC 2014 in Berlin, next February?

- Why is a pharmacology-oriented session important for the participants?

 

My patient presents with "uncontrolled hypertension": how to screen for secondary causes and optimise drug treatment

RHC Asia-Pacific 2013 - Discover the new presentations from the second session.

In these 3 case-based presentations you can learn how to:

- conduct a personalised, step-by-step assessment of a patient presenting with "uncontrolled hypertension"

- better understand what information is key to conclude for  resistant hypertension of secondary causes

- optimise the combinations of antihypertensive drugs before concluding to "resistant essential hypertension"

Costas Tsioufis, European Society of Hypertension Secretary, joins the Resistant Hypertension Course Scientific Board

The Resistant Hypertension Course (“RHC”) Board is pleased to announce that Costas Tsioufis (Assistant Professor of Cardiology, University of Athens, Chief of Hypertension Unit, First Cardiology Clinic, University of Athens, Greece) is joining Felix Mahfoud as Co-Chairperson of the RHC 2014.  Costas Tsioufis will represent the European Society of Hypertension, where he currently holds the position of Secretary. 

Final 3-year report of the Symplicity HTN-1 study is published online in the Lancet

The Symplicity HTN-1 (n=150) was the first multicenter, proof-of-concept and safety study for patients with resistant arterial hypertension (mean age 57 years) undergoing catheter-based renal denervation. Patients in the Symplicity HTN-1 study were heavily medicated, taking an average of five antihypertensive drugs, and were still poorly controlled (office blood pressure 175/98mmHg). The primary endpoint was peri-procedural and safety of the treatment (n=45) after 1 and 12 month published in 2009 at the Lancet (1).

Pages